Crowe HAF / SeqOne Genomics
The company, which has already provided its
genome sequencing data analysis platform to more than 15 institutions
(university hospitals, private laboratories, etc.), is expanding
internationally and continues to develop its solutions for a wider circle of
professionals in order to improve and customise healthcare for cancer and rare
diseases patients.
SeqOne Genomics closes a €20 million Series A
round with Omnes, Mérieux Equity Partners and Software Club alongside its
historical investors, with Elaia remaining as the main shareholder